Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Abbott and Biotest to jointly develop autoimmune disease treatment

Abbott and Biotest to jointly develop autoimmune disease treatment

22nd June 2011

Abbott is allying with fellow healthcare company Biotest on the development and eventual commercialisation of a new antibody for autoimmune diseases.

The alliance will focus on the development of BT-061, a compound currently undergoing phase II clinical testing against rheumatoid arthritis and psoriasis, with preclinical studies having commenced to investigate other applications.

It is an anti-CD4 antibody that functions by activating the body's T-regulatory cells, strengthening the body's ability to prevent excessive immune reactions without causing depletion of CD4 positive T-cells.

Abbott and Biotest will jointly promote the drug in the five major European markets, including the UK, while the former company will also hold exclusive rights to market the drug worldwide.

Dr John Leonard, senior vice-president for global research and development at Abbott, said: "Though the research is still early, BT-061 has the potential to become an important treatment option for patients suffering from autoimmune diseases."

Last week, Abbott announced that it will begin a new clinical study in partnership with Reata Pharmaceuticals to investigate bardoxolone methyl as a treatment for chronic kidney disease and type 2 diabetes.ADNFCR-8000103-ID-800590118-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.